Estrella Immunopharma, Inc.
ESLAAnalyst Consensus
Rating Trend
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| D. Boral Capital | maintain | Buy | Feb 9, 2026 |
| D. Boral Capital | maintain | Buy | Jan 28, 2026 |
| D. Boral Capital | maintain | Buy | Nov 3, 2025 |
| D. Boral Capital | maintain | Buy | Aug 12, 2025 |
| D. Boral Capital | maintain | Buy | Jun 3, 2025 |
| D. Boral Capital | maintain | Buy | May 29, 2025 |
| D. Boral Capital | maintain | Buy | Feb 21, 2025 |
Earnings History
Next report: Dec 2, 2026 · EPS est. $-0.08| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 13, 2026 | $-0.05 | $-0.05 | — | — |
| May 13, 2026 | $-0.05 | $-0.08 | — | — |
| Mar 18, 2026 | $-0.14 | $-0.18 | — | — |
| Nov 12, 2025 | $-0.13 | $-0.19 | — | — |
| Aug 11, 2025 | $-0.15 | $-0.07 | — | — |
| May 14, 2025 | $-0.06 | $-0.11 | — | — |
| Feb 15, 2025 | $-0.12 | $-0.12 | — | — |
| Nov 14, 2024 | $-0.09 | — | — | — |
News
EMERYVILLE, Calif.--(BUSINESS WIRE)--Estrella Immunopharma, Inc. (NASDAQ: ESLA) (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company developing next-generation ARTEMIS® T-cell therapies for the treatment of cancer and autoimmune diseases, today announced the appointment of Cynthia Pussinen as Chief Executive Officer and Chairperson of its Board of Directors, effective October 25, 2026. Ms. Pussinen succeeds Cheng Liu, Ph.D., as Chief Executive Officer. Dr. Liu has been appo.
EMERYVILLE, Calif.--(BUSINESS WIRE)--Estrella Immunopharma, Inc. (NASDAQ: ESLA) (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company developing CD19- and CD22-targeted ARTEMIS® T-cell therapies to treat cancers and autoimmune diseases, today announced that the first patient who received two infusions, each at 5 × 10⁶ EB103 T cells/kg, three weeks apart, in the dose-expansion phase has tolerated the study drug well in the first month, with no treatment-related serious advers.
EMERYVILLE, Calif.--(BUSINESS WIRE)--Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company developing CD19- and CD22-targeted ARTEMIS® T-cell therapies to treat cancers and autoimmune diseases, today announced the activation of a fifth clinical site for its ongoing STARLIGHT-1 Phase I/II clinical trial evaluating its investigational product candidate EB103, a CD19-Redirected ARTEMIS® T-cell therapy, in patients with relapsed o…
Shares of Estrella Immunopharma, Inc. (NASDAQ: ESLA - Get Free Report) shot up 1.1% during trading on Thursday. The stock traded as high as $0.77 and last traded at $0.7450. Approximately 29,691 shares changed hands during trading, a decline of 1% from the average daily volume of 30,025 shares. The stock had previously closed at
EMERYVILLE, Calif.--(BUSINESS WIRE)--Estrella Immunopharma, Inc. (NASDAQ: ESLA) (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced the activation of a fourth clinical site for its ongoing STARLIGHT-1 Phase I/II clinical trial evaluating EB103, a CD19-Redirected ARTEMIS® T-cell therapy, in patients with relapsed or refractory (R/R) B-cell non-Hodgkin's lymph.